Medline (NASDAQ:MDLN - Get Free Report) was upgraded by stock analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Wednesday, Zacks reports.
Other analysts have also recently issued research reports about the stock. UBS Group increased their price target on shares of Medline from $43.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. Royal Bank Of Canada dropped their price target on shares of Medline from $53.00 to $46.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Deutsche Bank set a $37.00 target price on Medline and gave the company a "hold" rating in a report on Thursday, August 6th. Citigroup lifted their target price on shares of Medline from $45.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Finally, William Blair reaffirmed an "outperform" rating on shares of Medline in a report on Wednesday, September 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Medline has a consensus rating of "Moderate Buy" and an average price target of $46.08.
Read Our Latest Research Report on MDLN
Medline Trading Down 3.4%
Shares of MDLN stock opened at $37.84 on Wednesday. Medline has a 1-year low of $31.37 and a 1-year high of $50.88. The firm has a market cap of $49.77 billion and a PE ratio of 86.00. The company has a 50-day moving average of $35.60 and a two-hundred day moving average of $39.25. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51.
Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.12. Medline had a net margin of 1.84% and a return on equity of 8.21%. The business had revenue of $7.86 billion for the quarter. On average, analysts predict that Medline will post 1.58 EPS for the current year.
Insider Transactions at Medline
In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares of the company's stock, valued at approximately $715,182,924.05. This represents a 11.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 6,348,676 shares of company stock worth $224,525,137. Insiders own 0.81% of the company's stock.
Hedge Funds Weigh In On Medline
A number of large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its position in shares of Medline by 8.4% during the 1st quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company's stock valued at $506,546,000 after acquiring an additional 887,240 shares during the period. Banque Pictet & Cie SA raised its holdings in shares of Medline by 2.0% in the third quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company's stock worth $258,692,000 after acquiring an additional 142,939 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Medline by 233.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company's stock valued at $222,500,000 after acquiring an additional 3,500,000 shares in the last quarter. Durable Capital Partners LP boosted its stake in shares of Medline by 80.2% during the third quarter. Durable Capital Partners LP now owns 4,734,627 shares of the company's stock valued at $164,292,000 after acquiring an additional 2,107,306 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Medline by 30,255.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company's stock worth $94,353,000 after purchasing an additional 2,691,529 shares in the last quarter.
Key Headlines Impacting Medline
These are some of the MDLN headlines that stood out recently:
- Positive Sentiment: Several recent valuation articles argue Medline may be undervalued, estimating upside of about 19% to 33%; a separate report says analysts raised fair-value estimates. These are valuation opinions, not guarantees of future performance. Article Article Article
- Positive Sentiment: Medline and its holding company plan a $200 million repurchase alongside the offering, providing some demand for shares, although the buyback is conditional on the offering closing. Company announcement
- Neutral Sentiment: Unusually high call-option trading was reported, but options activity alone does not establish a lasting bullish outlook. Medline also introduced right-sized packaging at two distribution centers, a potential operational-efficiency measure with no disclosed financial impact. Company announcement
Medline Company Profile
(
Get Free Report)
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medline, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medline wasn't on the list.
While Medline currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.